Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study

• DOI: 10.1002/clc.4960140211
• Publication Date: 2009-02-04T17:13:44Z
• Authors: P. H. Jones; J. A. Farmer; M. D. Cressman; J. M. Mckenney; J. T. Wright; J. D. Proctor; D. M. Berkson; D. J. Farnham; P. M. Wolfson; H. T. Colfer; C. E. Rackley; W. R. Sigmund; R. C. Schlant; D. Arensberg; M. E. Mcgovern
• Keywords: Bedtime; Hydroxymethylglutaryl-CoA reductase

This multicenter, double-blind, placebo-controlled study was conducted to evaluate dose-response effects and safety of once-daily administration pravastatin, a new inhibitor 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Pravastatin 5, 10, 20, 40 mg or placebo administered at bedtime 150 patients with primary hypercholesterolemia inadequately controlled on low-fat, low-cholesterol (AHA Phase I) diet. After 8 weeks treatment, pravastatin produced dose-dependent reductions in low-density lipoprotein (LDL) cholesterol 19.2 34.1% (p less than equal .001 vs. baseline placebo) total 14.3 25.1% .01 p baseline). The relationship between the loge dose decrease LDL linear 0.002). High-density-lipoprotein increased up 11.7% triglycerides decreased by as much 23.9%. well tolerated; no patient withdrew from consequence treatment-related adverse events. Despite its relatively short serum half-life approximately 2 h, provides safe effective means reducing elevated cholesterol.